N@N

Shortage of Novo's Wegovy and Ozempic is resolved, FDA website shows

The shortage of Novo Nordisk's weight-loss and diabetes drugs, Wegovy and Ozempic, has been resolved according to the U.S. Food and Drug Administration's (FDA) website. Previously, there were supply issues due to high demand, but the FDA now lists all dose strengths of Wegovy and Ozempic as available. This resolution comes after Novo Nordisk had to limit the supply of certain doses to ensure continuity for existing patients. The drugs, which use the active ingredient semaglutide, have seen increased demand due to their effectiveness in managing type 2 diabetes and aiding weight loss. The availability update was reflected on the FDA's website, signaling an end to the intermittent shortages that had affected patients' access to these medications.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/health/other/shortage-of-novo-s-wegovy-and-ozempic-is-resolved-fda-website-shows/ar-AA1zwwcE ]